Cannabidiol - GW Pharmaceuticals

Drug Profile

Cannabidiol - GW Pharmaceuticals

Alternative Names: CBD - GW Pharmaceuticals; Epidiolex; GW-42003; GWP-42003; GWP-42003-P

Latest Information Update: 18 May 2017

Price : $50

At a glance

  • Originator GW Pharmaceuticals
  • Developer GW Pharmaceuticals; University of Alabama at Birmingham; University of Utah
  • Class Analgesics; Antiepileptic drugs; Antipsychotics; Anxiolytics; Cannabinoids; Muscle relaxants; Neuroprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action Antioxidants; Cannabinoid receptor CB1 antagonists; Cannabinoid receptor CB2 antagonists; Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome; Dravet syndrome; Cerebral ischaemia; Infantile spasms; Tuberous sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dravet syndrome; Infantile spasms; Lennox-Gastaut syndrome; Tuberous sclerosis
  • Phase II Epilepsy; Opioid abuse; Parkinson's disease; Schizophrenia
  • Phase I Cerebral ischaemia
  • Preclinical Duchenne muscular dystrophy; Ovarian cancer
  • Discontinued Dyslipidaemias; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 09 May 2017 GW Pharmaceuticals' cannabidiol receives conditional grant of Rare paediatric disease designation from US FDA
  • 09 May 2017 GW Pharmaceuticals completes a phase I trial in Cerebral ischaemia in USA
  • 18 Apr 2017 Updated efficacy and adverse events data from a phase III trial in Lennox-Gastaut syndrome released by GW Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top